Eyas N Al-Mousa - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Expert Opinion on Pharmacotherapy|May 28, 2004

The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trialsAmar M Salam, Eyas N Al-Mousa

Saudi Medical Journal|July 6, 2004

Immunological changes in acute myocardial infarctionRanda S Al-Ahmad, Azmi M Mahafzah, Eyas N Al-Mousa

Saudi Medical Journal|April 5, 2005

Successful treatment of Brucella endocarditis with aortic root abscessAbdal-Rahman H Alhyari, Faris G Bakri, Eyas N Al-Mousa, et al.

Asiaintervention|December 9, 2022

Incidence and impact on prognosis of impaired kidney function in Middle Eastern patients undergoing percutaneous coronary intervention: results from the first Jordanian PCI RegistryAyman J Hammoudeh, Nahla Al-Bayyari, Omar Obeidat, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Expert Opinion on Pharmacotherapy|May 28, 2004

The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trialsAmar M Salam, Eyas N Al-Mousa

Saudi Medical Journal|July 6, 2004

Immunological changes in acute myocardial infarctionRanda S Al-Ahmad, Azmi M Mahafzah, Eyas N Al-Mousa

Saudi Medical Journal|April 5, 2005

Successful treatment of Brucella endocarditis with aortic root abscessAbdal-Rahman H Alhyari, Faris G Bakri, Eyas N Al-Mousa, et al.

Asiaintervention|December 9, 2022

Incidence and impact on prognosis of impaired kidney function in Middle Eastern patients undergoing percutaneous coronary intervention: results from the first Jordanian PCI RegistryAyman J Hammoudeh, Nahla Al-Bayyari, Omar Obeidat, et al.

Pageof 1